{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:54:57Z","timestamp":1791914097315,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41591-024-03301-2","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:06:54Z","timestamp":1730700414000},"page":"315-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-0066","authenticated-orcid":false,"given":"Hanna","family":"Pulaski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-2204","authenticated-orcid":false,"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena C.","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laryssa C.","family":"Manigat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hypatia","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P.","family":"Madasu Christudoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-2607","authenticated-orcid":false,"given":"Adam","family":"Stanford-Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0910-2655","authenticated-orcid":false,"given":"Jonathan","family":"Glickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristin E.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhan","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-4964","authenticated-orcid":false,"given":"Scott D.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Sejling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Minnich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Baxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mani","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-3791","authenticated-orcid":false,"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Montalto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick P.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-134X","authenticated-orcid":false,"given":"Andrew H.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7761-3637","authenticated-orcid":false,"given":"Katy E.","family":"Wack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"3301_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"3301_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"3301_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","volume":"113","author":"M Noureddin","year":"2018","unstructured":"Noureddin, M. et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am. J. Gastroenterol. 113, 1649\u20131659 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"3301_CR4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"3301_CR5","unstructured":"FDA\u2013NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and other Tools) Resource (2016); https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/"},{"key":"3301_CR6","unstructured":"Food and Drug Administration. Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry \u2014 Draft www.fda.gov\/media\/127738\/download (2019)."},{"key":"3301_CR7","unstructured":"Food and Drug Administration. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry www.fda.gov\/media\/119044\/download (2018)."},{"key":"3301_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.30418","volume":"70","author":"EM Brunt","year":"2019","unstructured":"Brunt, E. M., Kleiner, D. E., Wilson, L. A., Sanyal, A. J. & Neuschwander\u2010Tetri, B. A. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials. Hepatology 70, 522\u2013531 (2019).","journal-title":"Hepatology"},{"key":"3301_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41401-022-00874-x","volume":"43","author":"XF Tong","year":"2022","unstructured":"Tong, X. F. et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol. Sin. 43, 1200\u20131209 (2022).","journal-title":"Acta Pharmacol. Sin."},{"key":"3301_CR10","unstructured":"European Medicines Agency. Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Non-Alcoholic Steatohepatitis (NASH) (EMA\/CHMP\/111529\/2024) www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf (2023)."},{"key":"3301_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3301_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000325","volume":"8","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A. J. et al. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: data from a phase 3 study. Hepatol. Commun. 8, e0325 (2024).","journal-title":"Hepatol. Commun."},{"key":"3301_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131325 (2005).","journal-title":"Hepatology"},{"key":"3301_CR14","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison, B. A. et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 73, 1322\u20131332 (2020).","journal-title":"J. Hepatol."},{"key":"3301_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/hep.21346","volume":"44","author":"RB Merriman","year":"2006","unstructured":"Merriman, R. B. et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44, 874\u2013880 (2006).","journal-title":"Hepatology"},{"key":"3301_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","volume":"45","author":"R Juluri","year":"2011","unstructured":"Juluri, R. et al. Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 45, 55\u201358 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"3301_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ajcp\/aqx011","volume":"147","author":"M Pavlides","year":"2017","unstructured":"Pavlides, M. et al. Interobserver variability in histologic evaluation of liver fibrosis using categorical and quantitative scores. Am. J. Clin. Pathol. 147, 364\u2013369 (2017).","journal-title":"Am. J. Clin. Pathol."},{"key":"3301_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J. Hepatol. 72, 613\u2013626 (2020).","journal-title":"J. Hepatol."},{"key":"3301_CR19","first-page":"e195","volume":"3","author":"UJ Muehlematter","year":"2021","unstructured":"Muehlematter, U. J., Daniore, P. & Vokinger, K. N. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015\u201320): a comparative analysis. Lancet Digit. Health 3, e195\u2013e203 (2021).","journal-title":"Lancet"},{"key":"3301_CR20","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41379-021-00794-x","volume":"34","author":"S Perincheri","year":"2021","unstructured":"Perincheri, S. et al. An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy. Mod. Pathol. 34, 1588\u20131595 (2021).","journal-title":"Mod. Pathol."},{"key":"3301_CR21","doi-asserted-by":"publisher","unstructured":"Iyer, J. S. et al. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03172-7 (2024).","DOI":"10.1038\/s41591-024-03172-7"},{"key":"3301_CR22","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","volume":"76","author":"EM Brunt","year":"2022","unstructured":"Brunt, E. M. et al. Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD. J. Hepatol. 76, 1030\u20131041 (2022).","journal-title":"J. Hepatol."},{"key":"3301_CR23","doi-asserted-by":"publisher","unstructured":"Pulaski, H. et al. Validation of whole slide image management system for metabolic-associated steatohepatitis for clinical trials. J. Pathol. Clin. Res. 10, e12395 (2024); https:\/\/doi.org\/10.1002\/2056-4538.12395","DOI":"10.1002\/2056-4538.12395"},{"key":"3301_CR24","unstructured":"Loomba, R. et al. Comparison of the effects of semaglutide on liver histology in patients with non-alcoholic steatohepatitis cirrhosis between machine learning model assessment and pathologist evaluation (Poster presentation). 2022 American Association for the Study of Liver Diseases (AASLD). https:\/\/pathaiwp.wpenginepowered.com\/wp-content\/uploads\/2023\/01\/FINAL_Loomba_AASLD_PathAI-key-results_poster_Approval-Draft_26Oct22.pdf (2022)."},{"key":"3301_CR25","first-page":"1415A","volume":"74","author":"DE Shevell","year":"2021","unstructured":"Shevell DE, Brown E, Du S, et al. Comparison of manual vs machine learning approaches to liver biopsy scoring for NASH and fibrosis: A post hoc analysis of the FALCON 1 study. Hepatology 74, 1415A (2021).","journal-title":"Hepatology"},{"key":"3301_CR26","doi-asserted-by":"publisher","first-page":"S711","DOI":"10.1016\/S0168-8278(22)01740-8","volume":"7","author":"S Harrison","year":"2022","unstructured":"Harrison, S. et al. Retrospective AI-based measurement of NASH histology (AIM-NASH) analysis of biopsies from Phase 2 study of Resmetirom confirms significant treatment-induced changes in histologic features of non-alcoholic steatohepatitis. J. Hepatol. 7, S711\u2013S712 (2022).","journal-title":"J. Hepatol."},{"key":"3301_CR27","first-page":"E56","volume":"79","author":"J Iyer","year":"2023","unstructured":"Iyer, J. et al. Artificial intelligence-based measurement of NASH histology (AIM-NASH) recapitulates primary results from phase 3 study of resmetirom for treatment of NASH\/MASH. Hepatology 79, E56\u2013E57 (2023).","journal-title":"Hepatology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03301-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:03:44Z","timestamp":1737482624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03301-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3301"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03301-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.P., H.H., A.S.-M., R.E., N.P., A.H.B. and N.P.A. are full-time, salaried employees of PathAI. K.E.W. was a full-time employee of PathAI during all phases of the study and is now a paid consultant of PathAI. S.A.H. is a paid consultant for Akero Therapeutics, Aligos Therapeutics, Altimmune, Boehringer Ingelheim, Bluejay Therapeutics, Echosens North America, Galecto, Gilead Sciences, GlaxoSmithKline, Hepion Pharmaceuticals, Hepta Bio, HistoIndex, Kriya Therapeutics, Madrigal Pharmaceuticals, Medpace, MGGM Therapeutics, NeuroBo Pharmaceuticals, Northsea Therapeutics, Novo Nordisk, Pfizer, Sagimet Biosciences, Terns and Viking Therapeutics and a shareholder of Akero, Cirius Therapeutics, Galectin Therapeutics, HistoIndex and Northsea Therapeutics. S.S.M., M.C.V., L.C.M., S.P.M.C., S.H.M., C.E.T. and M.C.M. were PathAI employees at the time of study conduct. J.G. and M.R. are paid contractors of PathAI. R.P.M. and G.M.S. are full-time, salaried employees of OrsoBio. C.C. is a full-time, salaried employee of Inipharm. S.D.P. is a full-time salaried employee of Gilead Sciences. A.-S.S. is a full-time, salaried employee of Novo Nordisk. A.M. was a paid consultant for Bristol Myers Squibb. V.B. is a full-time, salaried employee of Bristol Myers Squibb. A.J.S. has stock options in Genfit, Akarna, Tiziana, Indalo, Durect Inversago and Galmed; is a consultant to AstraZeneca, Nimbus, Takeda, Janssen, Gilead, Terns, Merck, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Novartis, Novo Nordisk, Pfizer and Genfit; and has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin and Affimune Prosciento. His institution has received grant support from Gilead, Bristol Myers Squibb, Intercept, Merck, AstraZeneca and Novartis. He receives royalties from Elsevier and UptoDate. Q.M.A. is a coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 program and the EFPIA. This multistakeholder consortium includes industry partners. He has research grant funding from AstraZeneca, Boehringer Ingelheim and Intercept. He is a consultant on behalf of Newcastle University to Alimentiv, Akero, AstraZeneca, 89bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKline, HistoIndex, Intercept, Inventiva, QVIA, Janssen, Madrigal, Merck, NGM Bio, Novartis, Novo Nordisk, PathAI, Pfizer, PharmaNest, Prosciento, Roche and Terns. He is a speaker for Novo Nordisk, Madrigal and Springer Healthcare and receives royalties from Elsevier. R.L. is a consultant to Aardvark Therapeutics, Altimmune, Alnylam\u2013Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bluejay Therapeutics, Bristol Myers Squibb, Eli Lilly, Galmed, Gilead, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89bio, Terns Pharmaceuticals and Viking Therapeutics. He is a cofounder of LipoNexus. V.R. is a paid consultant for Novo Nordisk, Northsea Madrigal, Enyo, Poxel, Bristol Myers Squibb, Intercept, NGM Bio and Sagimet.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}